Enosi Therapeutics Overview
- Year Founded
-
2018
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
Enosi Therapeutics General Information
Description
Developer of therapeutics research designed to treat autoimmune diseases and cancer through advanced immunology and antibody research. The company focuses on drug research and development by combining expertise in tumor necrosis factor therapies, monoclonal antibodies, and oncology research, enabling healthcare providers to access expanded therapeutic options for complex immune and cancer-related diseases.
Contact Information
Website
www.enositherapeutics.comCorporate Office
- 590 Pearl Street
- Suite 311
- Eugene, OR 97401
- United States
Corporate Office
- 590 Pearl Street
- Suite 311
- Eugene, OR 97401
- United States
Enosi Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 04-Oct-2026 | Completed | Out of Business | |||
| 3. Equity Crowdfunding | 10-Jul-2022 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 31-Aug-2020 | Cancelled | Generating Revenue | |||
| 1. Corporate | 22-Jan-2020 | Completed | Generating Revenue |
Enosi Therapeutics Comparisons
Industry
Financing
Details
Enosi Therapeutics Competitors (1)
One of Enosi Therapeutics’s competitors is INmune Bio, a Formerly VC-backed company based in Boca Raton, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| INmune Bio | Formerly VC-backed | Boca Raton, FL |
Enosi Therapeutics Patents
Enosi Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250388650-A1 | Oligo-trap fusion proteins (ofps) and uses thereof | Pending | 07-Sep-2023 | ||
| EP-4784619-A1 | Tnfr1 antagonists lacking agonist activity and uses thereof | Pending | 29-Aug-2023 | ||
| US-20260209374-A1 | Tnfr1 antagonists lacking agonist activity and uses thereof | Pending | 29-Aug-2023 | ||
| WO-2025049818-A1 | Tnfr1 antagonists lacking agonist activity and uses thereof | Inactive | 29-Aug-2023 | ||
| WO-2024186690-A2 | Oligo-trap fusion proteins (ofps) and uses thereof | Inactive | 03-Mar-2023 | C07K14/82 |
Enosi Therapeutics Signals
Enosi Therapeutics FAQs
-
When was Enosi Therapeutics founded?
Enosi Therapeutics was founded in 2018.
-
Where is Enosi Therapeutics headquartered?
Enosi Therapeutics is headquartered in Eugene, OR.
-
What is the size of Enosi Therapeutics?
Enosi Therapeutics has 2 total employees.
-
What industry is Enosi Therapeutics in?
Enosi Therapeutics’s primary industry is Drug Discovery.
-
Is Enosi Therapeutics a private or public company?
Enosi Therapeutics is a Private company.
-
What is Enosi Therapeutics’s current revenue?
The current revenue for Enosi Therapeutics is .
-
How much funding has Enosi Therapeutics raised over time?
Enosi Therapeutics has raised $164K.
-
Who are Enosi Therapeutics’s competitors?
INmune Bio is a competitor of Enosi Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process